News

The investigational extended-release tablet maintained therapeutic plasma levels while avoiding peaks linked to cardiovascular risk.

Brian Kim, MD, FAAD, explores the transformative role of neuroimmunology in dermatology, urging a shift towards systems-level therapeutic strategies.

Explore the vital role of dermatology in breast cancer care, from early detection to managing skin issues related to treatment and radiation.

The approval represents the sixth FDA authorization for roflumilast since 2022.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about the FDA approvals of guselkumab for pediatric plaque psoriasis and PsA, along with remibrutinib for CSU, LEO Pharma's acquisition of spesolimab for GPP, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Spesolimab joins LEO Pharma’s dermatology portfolio to further expand spesolimab’s reach for patients worldwide with generalized pustular psoriasis.

Brian Kim, MD, FAAD, explores the Cell Symposia: Neuro-immune Axis, highlighting neuroimmunology's impact on dermatology and systemic medicine.

WHO includes adalimumab and ustekinumab for psoriasis, plus sunscreen for albinism, enhancing global skin health and access to essential treatments.

Quality of life improvements paralleled clinical efficacy in the CUPID studies of dupilumab.

Trial data show up to 30% of patients achieved complete response and 70% demonstrated some benefit from treatment.

Lisa Espinoza, MD, highlights the importance of patient education and tailored HA filler treatments for achieving natural cosmetic results.

Disc Medicine filed an NDA for bitopertin to treat erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) in patients ≥12 years.

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, shares how Apex Skin is improving trial adherence through bilingual staff, modernizing operations with digital tools, and strengthening community partnerships.

The vaccine is designed to stimulate T cell responses against IDO1- and PD-L1–positive cells within the tumor microenvironment.

Heather Gates, PA-C, brings her dermatology expertise into a conference management business to enhance education for professionals of all levels.

ORKA-001 builds on the proven success of existing IL-23 inhibitors used in psoriasis treatment.

Lisa Espinoza, MD, discusses key insights from Allergan's Hyaluronic Acid Injectable Fillers Report, highlighting patient satisfaction and evolving aesthetic trends.

Patient advocate Danielle Jonas shares her journey with atopic dermatitis, emphasizing the importance of trusted products and clinician support during Eczema Awareness Month.

World Urticaria Day raises awareness about chronic spontaneous and inducible urticaria, highlighting treatment advancements and patient challenges.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of October.

While VELA-1 achieved statistical significance under all analyses, VELA-2 narrowly missed its composite primary endpoint due to higher-than-expected placebo outcomes.

Explore insights from Renata Block DMSc, MMS, PA-C, and James Del Rosso, DO, on interpreting clinical trial data in dermatology for enhanced patient care and outcomes.

Fewer than 20% of eligible patients currently receive injectable therapies, highlighting the need for oral alternatives.

Dermatology Times is looking back on the top stories in dermatology from the month of September.

Test your knowledge of key words and terms associated with dermatology news from the last month.

Both treatments were well tolerated, with only mild, self-limiting adverse effects reported.

Dermatology Times is recapping our exclusive expert interviews from the month of September.